<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>37(3)</volume><submitter>Sbarigia U</submitter><funding>Janssen Scientific Affairs, LLC</funding><pubmed_abstract>&lt;h4>Introduction&lt;/h4>This study aimed to characterize chronic hepatitis B (CHB)-infected patients and estimate the association between nucleos(t)ide analogue (NA) persistence and economic outcomes using data from the Veterans Health Administration (VHA) database.&lt;h4>Methods&lt;/h4>Patients (at least 18 years of age) with two or more claims for CHB and at least one pharmacy claim for NA were identified using VHA data from 1 April 2013 to 31 March 2018. The index date was the first NA prescription fill date during 1 October 2014 to 31 March 2017. Persistence and non-persistence to NA treatment were assessed during the first 2 years post index date. Non-persistence was defined as at least one failure to refill medication within 30 days from the run-out date. Generalized linear models were used t</pubmed_abstract><journal>Advances in therapy</journal><pagination>1156-1172</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7089729</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Evaluating the Effect of Standard of Care Treatment on Burden of Chronic Hepatitis B: A Retrospective Analysis of the United States Veterans Population.</pubmed_title><pmcid>PMC7089729</pmcid><pubmed_authors>Katz EG</pubmed_authors><pubmed_authors>Colasurdo J</pubmed_authors><pubmed_authors>Xie L</pubmed_authors><pubmed_authors>Sah J</pubmed_authors><pubmed_authors>Sylvester S</pubmed_authors><pubmed_authors>Sbarigia U</pubmed_authors><pubmed_authors>Kariburyo F</pubmed_authors></additional><is_claimable>false</is_claimable><name>Evaluating the Effect of Standard of Care Treatment on Burden of Chronic Hepatitis B: A Retrospective Analysis of the United States Veterans Population.</name><description>&lt;h4>Introduction&lt;/h4>This study aimed to characterize chronic hepatitis B (CHB)-infected patients and estimate the association between nucleos(t)ide analogue (NA) persistence and economic outcomes using data from the Veterans Health Administration (VHA) database.&lt;h4>Methods&lt;/h4>Patients (at least 18 years of age) with two or more claims for CHB and at least one pharmacy claim for NA were identified using VHA data from 1 April 2013 to 31 March 2018. The index date was the first NA prescription fill date during 1 October 2014 to 31 March 2017. Persistence and non-persistence to NA treatment were assessed during the first 2 years post index date. Non-persistence was defined as at least one failure to refill medication within 30 days from the run-out date. Generalized linear models were used t</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Mar</publication><modification>2025-04-18T18:39:35.955Z</modification><creation>2020-05-22T14:24:41Z</creation></dates><accession>S-EPMC7089729</accession><cross_references><pubmed>32009232</pubmed><doi>10.1007/s12325-020-01240-1</doi></cross_references></HashMap>